Literature DB >> 22004427

Effects of magnolol on vascular contraction in rat aortic rings.

Young Mi Seok1, Hye Young Kim, Otgonbayar Garmaa, Byung-Yoon Cha, Je-Tae Woo, In Kyeom Kim.   

Abstract

1. Magnolol (5,5'-diallyl-2,2'-dihydroxybiphenyl) is a major phenolic compound purified from Magnolia officinalis. The aim of the present study was to elucidate the effects of magnolol on vascular contractions. 2. Rat aortic rings were mounted in organ baths. Magnolol was added cumulatively (0.3-30 μmol/L) to elicit relaxation in endothelium-intact and -denuded rat aortic rings precontracted with U46619 (30 nmol/L, 20 min), NaF (8.0 mmol/L, 40 min), phenylephrine (1.0 or 0.1 μmol/L, 15 min) or phorbol-12,13-dibutyrate (PDBu, 0.3 or 0.1 μmol/L, 40 min). In separate experiments, cumulative concentrationresponse curves were obtained for NaF (2.0-12 mmol/L), U46619 (1.0 nmol/L1.0 μmol/L) or PDBu (1.0 nmol/L1.0 μmol/L) after pretreatment with either magnolol or vehicle for 30 min in endothelium-denuded aortic rings. After completion of the functional study, we measured the amount of guanosine triphosphate (GTP) RhoA by using a G-LISA RhoA Activation Assay, as well as the phosphorylation of 20 kDa myosin light chain (MLC₂₀), myosin phosphatase-targeting subunit 1 (MYPT1) and protein kinase C-potentiated inhibitory protein for heterotrimeric myosin light-chain phosphatase of 17 kDa (CPI-17) by immunobloting. 3. Magnolol (0.3-30 μmol/L) reduced vascular tension induced by the thromboxane A₂ agonist U46619 (30 nmol/L), sodium fluoride (NaF) (8.0 mmol/L) and the α₁ -adrenoceptor agonist phenylephrine (1.0 or 0.1 μmol/L) in both endothelium-intact and -denuded rings. The magnitude of the relaxation effects of magnolol on the contraction induced by each of the drugs were similar. The magnitude of the effect of magnolol in endothelium-intact and -denuded rings were similar. 4. Pretreatment of rat aortic rings with 1.0, 3.0 or 10 μmol/L magnolol for 30 min dose-dependently inhibited the maximum response on the concentration-response curves to NaF and U46619, but not to phorbol-12,13-dibutyrate (PDBu). 5. Magnolol (3.0 or 10 μmol/L) decreased RhoA activation, as well as the phosphorylation of MLC₂₀ , MYPT1(Thr855) and CPI-17(Thr38) induced by either 8.0 mmol/L NaF or 30 nmol/L U46619. In contrast, magnolol did not affect PDBu (0.1 μmol/L)-induced phosphorylation of CPI-17(Thr38) . 6. In conclusion, magnolol reduces vascular contraction by inhibiting the RhoA/Rho kinase pathway in endothelium-denuded rat aorta.
© 2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22004427     DOI: 10.1111/j.1440-1681.2011.05629.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  3 in total

1.  Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death.

Authors:  Daniel Herrmann; Andrea Schreiber; Anna Ciotkowska; Frank Strittmatter; Raphaela Waidelich; Christian G Stief; Christian Gratzke; Martin Hennenberg
Journal:  Prostate Int       Date:  2014-08-26

2.  Histone deacetylase inhibitor LMK235 attenuates vascular constriction and aortic remodelling in hypertension.

Authors:  Sin Young Choi; Hae Jin Kee; Simei Sun; Young Mi Seok; Yuhee Ryu; Gwi Ran Kim; Seung-Jung Kee; Marc Pflieger; Thomas Kurz; Matthias U Kassack; Myung Ho Jeong
Journal:  J Cell Mol Med       Date:  2019-02-07       Impact factor: 5.310

3.  Detection of Vasodilators From Herbal Components by a Transcriptome-Based Functional Gene Module Reference Approach.

Authors:  Peng Li; Chang Chen; Wuxia Zhang; Dingrong Yu; Shaoyan Liu; Jinzhong Zhao; An Liu
Journal:  Front Pharmacol       Date:  2019-10-02       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.